Janney Montgomery Scott LLC Purchases 90,761 Shares of Zoetis Inc. $ZTS

Janney Montgomery Scott LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 138.7% during the first quarter, HoldingsChannel reports. The firm owned 156,212 shares of the company’s stock after purchasing an additional 90,761 shares during the period. Janney Montgomery Scott LLC’s holdings in Zoetis were worth $18,466,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Brighton Jones LLC grew its holdings in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC increased its position in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after buying an additional 657 shares during the period. Intech Investment Management LLC lifted its holdings in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after buying an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC boosted its position in shares of Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after acquiring an additional 1,422 shares during the period. Finally, Glenview Trust co boosted its position in shares of Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after acquiring an additional 506 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 11,650 shares of company stock worth $886,384 in the last 90 days. 0.22% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ZTS shares. JPMorgan Chase & Co. dropped their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Citigroup dropped their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and an average target price of $130.85.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: TD Cowen lowered its price target on Zoetis to $104 from $150 but maintained a “buy” rating, suggesting analysts still see meaningful upside from current levels. Benzinga
• Neutral Sentiment: Zoetis reported a mixed earnings quarter earlier this year, with revenue and EPS both slightly below expectations, which may continue to weigh on sentiment.
• Negative Sentiment: Several law firms issued repeated alerts about an existing class-action lawsuit against Zoetis, signaling ongoing legal overhang and potential distraction/costs for the company. GlobeNewswire
• Negative Sentiment: Some complaint summaries allege a “companion animal segment collapse,” reinforcing investor concerns about Zoetis’ growth outlook and execution. GlobeNewswire

Zoetis Price Performance

Shares of Zoetis stock opened at $71.88 on Wednesday. The firm has a market cap of $30.13 billion, a P/E ratio of 11.92, a price-to-earnings-growth ratio of 1.14 and a beta of 0.75. The firm’s 50-day simple moving average is $86.77 and its 200-day simple moving average is $110.27. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $161.77. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.